2025– date –

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In this fifth edition, we shift our focus to clinical applicat...

For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In particular, the design of co-stimulatory molecules and intracellular signaling domains directly impacts the treatment'...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. We explore how “smart control” of CAR expression—targeting tumor...

In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. This time, we take a deep dive into the underlying technologies that make “in vivo CAR-T” possible. F...

CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio...

Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. This bonus chapter highlights recen...

Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th...

In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige...

Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, we introduce the three fundamental components of ADCs—antibody, linker, and payload—explaining their functio...

Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 1)What Are Slimming Drugs? A Gentle Introduction to Anti-Obesity Medications Welcome to the Morningglorysciences Summer Special Beginner Series!This series is designed for reader...

[Review] A Landmark Overview on Stem Cell Aging, Cell Stem Cell 2025 Introduction As we age, one of the most fundamental biological changes is the decline in stem cell function. Stem cells are essential for maintaining tissue homeostasis...

BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ...

A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar...

New Hypothesis Links Stress, the Brain, and Systemic Aging In the June 2025 issue of Nature (Vol.642), researchers from Columbia University led by Dr. Martin Picard proposed that senescent cells—those associated with aging—may consume do...

Introduction Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution amidst global competition. Daiichi Sankyo, Takeda, Otsuka, and Astellas have each leveraged their strengths to enhance compet...

Introduction Between 2015 and 2025, global pharmaceutical giants have expanded into innovative therapeutic areas and pursued internalization or adoption of novel technologies. Based on the strategic movements of 22 companies, this articl...

Screenshot Human Brain Organoids Reveal Therapeutic Potential for Rare Pediatric Epilepsy In June 2025, a research team led by Dr. Heather Mefford at St. Jude Children’s Research Hospital reported a groundbreaking study using human brain...

[FDA Accelerated Approval] New Oral TKI for Advanced NSCLC with EGFR Exon20 Insertions On July 2, 2025, the FDA granted accelerated approval to Sunvozertinib (brand name: Zegfrovy) for the treatment of adult patients with locally advance...